ArticleOncotarget2017

Polo-like-kinase 1 (PLK-1) and c-myc inhibition with the dual kinase-bromodomain inhibitor volasertib in aggressive lymphomas.

Carlos Murga-Zamalloa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.